Literature DB >> 24607066

Race- and sex-associated differences in rate-adjusted QT, QTpeak, ST elevation and other regional measures of repolarization: the Atherosclerosis Risk in Communities (ARIC) Study.

Pentti M Rautaharju1, Zhu-Ming Zhang2, Wesley K Haisty3, Richard E Gregg4, James Warren5, Milan B Horaĉek5, Anna M Kucharska-Newton6, Wayne Rosamond6, Elsayed Z Soliman7.   

Abstract

BACKGROUND: Data are limited about race-and sex-associated differences in prognostically important ECG measures of regional repolarization. METHODS AND
RESULTS: The normal reference group from the Atherosclerosis Risk in Communities (ARIC) study included 8,676 white and African-American men and women aged 40-65 years. Exclusion criteria included cardiovascular disease, hypertension, diabetes and major ECG abnormalities. Notable sex differences (p<0.001) were observed in the upper 98% limits for rate-adjusted QTend (QTea) which was 435 ms in white and African-American men and 445 ms in white and African-American women, and for left ventricular epicardial repolarization time (RTepi) which was 345 ms in white and African-American men and 465 ms in white and African-American women. These sex differences reflect earlier onset and end of repolarization in men than in women. Upper normal limits for STJ amplitude in V2-V3 were 100 μV in white and African-American women, 150 μV in white men and 200 μV in African-American men (p<0.001 for sex differences), and for other chest leads, aVL and aVF 50 μV in white women, 100 μV in African-American women, 100 μV in white men and 150 μV in African-American men (p<0.001 for sex and race differences).
CONCLUSIONS: Shorter QTea and RTepi in men than in women reflect earlier onset and end of repolarization in men. STJ amplitudes in African-American men were higher than in other subgroups by race and sex. These sex and race differences need to be considered in clinical and epidemiological applications of normal standards.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Electrocardiogram; QT; Race; ST-T wave; Sex

Mesh:

Year:  2014        PMID: 24607066     DOI: 10.1016/j.jelectrocard.2014.01.012

Source DB:  PubMed          Journal:  J Electrocardiol        ISSN: 0022-0736            Impact factor:   1.438


  6 in total

1.  Electrocardiograms in African Americans and Non-African Americans Presenting with Takotsubo Syndrome.

Authors:  John E Madias
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-06-02       Impact factor: 1.468

Review 2.  QT Interval Prolongation Associated With Cytotoxic and Targeted Cancer Therapeutics.

Authors:  Sanjay Chandrasekhar; Michael G Fradley
Journal:  Curr Treat Options Oncol       Date:  2019-05-25

3.  Long Noncoding RNA Kcna2 Antisense RNA Contributes to Ventricular Arrhythmias via Silencing Kcna2 in Rats With Congestive Heart Failure.

Authors:  Qing-Qing Long; Hao Wang; Wei Gao; Yi Fan; Ya-Fei Li; Yao Ma; Yang Yang; Hao-Jie Shi; Bing-Rui Chen; Hao-Yu Meng; Qi-Ming Wang; Fang Wang; Ze-Mu Wang; Lian-Sheng Wang
Journal:  J Am Heart Assoc       Date:  2017-12-20       Impact factor: 5.501

4.  Prevalence of ECGs Exceeding Thresholds for ST-Segment-Elevation Myocardial Infarction in Apparently Healthy Individuals: The Role of Ethnicity.

Authors:  C Cato Ter Haar; Jan A Kors; Ron J G Peters; Michael W T Tanck; Marieke B Snijder; Arie C Maan; Cees A Swenne; Bert-Jan H van den Born; Jonas S S G de Jong; Peter W Macfarlane; Pieter G Postema
Journal:  J Am Heart Assoc       Date:  2020-06-23       Impact factor: 5.501

Review 5.  Sexual Dimorphisms, Anti-Hormonal Therapy and Cardiac Arrhythmias.

Authors:  Virginie Grouthier; Melissa Y Y Moey; Estelle Gandjbakhch; Xavier Waintraub; Christian Funck-Brentano; Anne Bachelot; Joe-Elie Salem
Journal:  Int J Mol Sci       Date:  2021-02-02       Impact factor: 5.923

6.  Pharmacokinetics, safety, and cardiovascular tolerability of phenylephrine HCl 10, 20, and 30 mg after a single oral administration in healthy volunteers.

Authors:  Cathy K Gelotte; Brenda A Zimmerman
Journal:  Clin Drug Investig       Date:  2015-09       Impact factor: 2.859

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.